HER2-Negative Breast Cancer Global Market Report 2025

The HER2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period was driven by the rising incidence of breast cancer, increased awareness about the disease, higher healthcare spending, an aging population, and the expansion of healthcare infrastructure.

The HER2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period is expected to be driven by rising alcohol consumption, the adoption of unhealthy lifestyles, the increasing prevalence of obesity, higher tobacco use, and the growing need for effective treatment solutions. Key trends include innovations in diagnostic technologies, the integration of targeted therapies and immunotherapies, FDA approvals, and advancements in medical technology.

The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, typically originating in the ducts or lobules. Several factors contribute to the rising number of breast cancer cases, including heightened awareness and advancements in screening technologies, which lead to earlier and more frequent detection. HER2-negative breast cancer research is critical in understanding distinct tumor biology and developing targeted therapies that improve treatment outcomes. For example, in June 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2021, 272,454 new cases of breast cancer were diagnosed among females in the United States, with 42,211 deaths recorded in 2022. This growing prevalence underscores the increasing demand for effective HER2-negative breast cancer treatments.

Leading companies in the HER2-negative breast cancer market are actively pursuing regulatory approvals to introduce new treatments, expand their product offerings, and strengthen their market presence. Regulatory approvals represent official authorizations granted by government agencies, ensuring that drugs and treatments meet safety, efficacy, and quality standards before commercialization. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval enables Itovebi to be administered in combination with palbociclib and fulvestrant, significantly enhancing progression-free survival compared to standard treatments. The newly approved regimen offers a crucial treatment option for patients with limited alternatives, highlighting the importance of biomarker testing in identifying those most likely to benefit from the therapy.

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, partnered with Pfizer Inc. to evaluate the combination of atirimociclib, Pfizer’s investigational selective CDK4 inhibitor, with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. This collaboration seeks to leverage the distinct properties of both drugs to minimize off-target toxicity, which has historically limited the effectiveness of non-selective agents. Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, continues to play a key role in the development of innovative treatments for HER2-negative breast cancer.

Major players in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

HER2-negative breast cancer is a type of breast cancer in which the cancer cells do not overexpress the HER2 protein, which is responsible for promoting tumor growth. This form of cancer generally grows more slowly than HER2-positive breast cancer and is treated using targeted therapies and chemotherapy.

The primary treatment options for HER2-negative breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of powerful drugs to destroy or inhibit the growth of cancer cells by targeting rapidly dividing cells in the body. Treatment is administered at various stages, including the early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The HER2-negative breast cancer market research report is one of a series of new reports that provides HER2-negative breast cancer market statistics, including HER2-negative breast cancer industry global market size, regional shares, competitors with HER2-negative breast cancer market share, detailed HER2-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the HER2-negative breast cancer industry. This HER2-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.